Holen Sie sich die Stockscreener-App
1.325
4.76%
0.065
Schlusskurs vom Vortag:
$1.26
Offen:
$1.27
24-Stunden-Volumen:
8.45M
Relative Volume:
1.23
Marktkapitalisierung:
$398.64M
Einnahmen:
$160.01M
Nettoeinkommen (Verlust:
$-546.38M
KGV:
-0.7221
EPS:
-1.835
Netto-Cashflow:
$-118.92M
1W Leistung:
-5.04%
1M Leistung:
-21.43%
6M Leistung:
+3.13%
1J Leistung:
+11.86%
1-Tages-Spanne:
$1.27
$1.338
1-Wochen-Bereich:
$1.23
$1.45
52-Wochen-Spanne:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.32 | 380.52M | 160.01M | -546.38M | -118.92M | -1.835 |
ABT
Abbott Laboratories
|
102.47 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.77 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.72 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.40 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Returns Recap: Will Pacific Biosciences of California Inc outperform during market rallies2026 Patterns & Long-Term Capital Growth Strategies - baoquankhu1.vn
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN
Pacific Biosciences Stock: Long-Read Sequencing Leader Faces Evolving Genomics Landscape - AD HOC NEWS
Stock List: Research Stocks from Around the World - GuruFocus
Stock Report: Can Pacific Biosciences of California Inc reach all time highs this year2026 Final Week & Real-Time Stock Movement Alerts - baoquankhu1.vn
Pacific Biosciences of California (PACB) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Vanguard amendment shows 0 PACB shares after realignment (PACB) - Stock Titan
Pacific Biosciences of California (PACB) Experiences a Sharper Decline Compared to the Market: Key Points to Consider - bitget.com
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates - MSN
PacBio Secures Agreement with Basecamp Research for Trillion Gene Atlas Project - bitget.com
Why The PacBio (PACB) Investment Story Is Shifting As Analysts Turn Cautious - Yahoo Finance
PacBio Wins Basecamp Research Deal for Trillion Gene Atlas Initiative - Eastern Progress
Panic Selling: Will Pacific Biosciences of California Inc outperform tech stocks2026 Macro Impact & AI Powered Market Entry Strategies - baoquankhu1.vn
Earnings Update: Should I invest in Pacific Biosciences of California Inc before earnings2026 Weekly Recap & Risk Managed Investment Strategies - baoquankhu1.vn
Pacific Biosciences of California grants early SPRQ-Nx beta access to scientists for HiFi sequencing - Traders Union
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Pacific Biosciences of California (PACB) Falls Further Than the Overall Market: Key Information to Note - Bitget
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Pacific Biosciences of California expands cancer research with new epigenetics lesson in sequencing series - Traders Union
DNA Sequencing Market size to hit $108.95 Billion by 2035 | Top - openPR.com
Canaccord reiterates Pacific Biosciences stock rating on new chemistry By Investing.com - Investing.com Canada
Canaccord reiterates Pacific Biosciences stock rating on new chemistry - Investing.com
PacBio (PACB) Collaborates on Groundbreaking Trillion Gene Atlas Project - GuruFocus
Pacific Biosciences (PACB) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative - marketscreener.com
Inside the trillion-gene atlas training AI to design new medicines - Stock Titan
Pacific Biosciences of California unveils DNA sequencing method boosting accuracy to 99.9 percent - Traders Union
Volume Summary: Does Pacific Biosciences of California Inc have a sustainable dividend2026 Geopolitical Influence & AI Forecasted Stock Moves - baoquankhu1.vn
Pacific Biosciences of California urges last call for webinar on HiFi sequencing advances in cancer research - Traders Union
PacBio and DNAstack collaborate on global HiFi genome network hub - MSN
Pacific Biosciences of California introduces HiFi sequencing for comprehensive cancer analysis - Traders Union
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio - geneonline.com
Pacific Biosciences of California technology maps cancer structural variants in single platform advance - Traders Union
PACB,TAL Options - Finviz
PACB,TAL Volatility & Greeks - Finviz
Chart Watch: Will Pacific Biosciences of California Inc outperform during market ralliesWeekly Earnings Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Why The PacBio (PACB) Investment Story Is Shifting As Analysts Cut Targets And Flag Risks - Yahoo Finance
HiFi sequencing enables automatic detection of 5mC and 6mA, Pacific Biosciences of California asserts - Traders Union
Pacific Biosciences of California reports prelim Q4, FY revenue above estimate - MSN
Pacific Biosciences Secures Key Patent License, Ends Litigation - TipRanks
Pacific Biosciences announces accounting officer transition and litigation settlement - Investing.com
Patent deal locks in protections for Pacific Biosciences (NASDAQ: PACB) with PGI - Stock Titan
Pacific Biosciences of California, Inc. Announces Chief Accounting Officer Changes, Effective March 21, 2026 - marketscreener.com
PACB - Finviz
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Finviz
PACB Analyst Rating Downgrade by Barclays to Underweight | PACB Stock News - GuruFocus
Pacific Biosciences of California (NASDAQ:PACB) Receives Underweight Rating from Barclays - MarketBeat
Barclays downgrades Pacific Biosciences stock rating on catalysts By Investing.com - Investing.com Canada
Barclays downgrades Pacific Biosciences stock rating on catalysts - Investing.com UK
PacBio Announces the Appointment of Chris Gibson to the Board of Directors - Sahm
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pacific Biosciences Of California Inc-Aktie (PACB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Van Oene Mark | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
6,504 |
9,847 |
2,243,634 |
| Farmer Michele | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
2,979 |
4,510 |
305,948 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):